On March 20, 2026, Aurinia Pharmaceuticals Inc. reported the departure of several key executives, including CEO Peter Greenleaf, and appointed Kevin Tang as new CEO, along with Ryan Cole and Michael Hearne in COO and CFO roles, respectively, effective March 23, 2026. This transition signifies a major alteration in leadership, aiming to enhance company direction and management.